Neuroderm Limited Ord (NASDAQ:NDRM) Short Interest Increased By 21.57%

July 17, 2017 - By Maria Brooks

 Neuroderm Limited Ord (NASDAQ:NDRM) Short Interest Increased By 21.57%

The stock of Neuroderm Limited Ord (NASDAQ:NDRM) registered an increase of 21.57% in short interest. NDRM’s total short interest was 1.42M shares in July as published by FINRA. Its up 21.57% from 1.17 million shares, reported previously. With 397,000 shares average volume, it will take short sellers 4 days to cover their NDRM’s short positions. The short interest to Neuroderm Limited Ord’s float is 12.8%.

The stock increased 4.69% or $1.4 during the last trading session, reaching $31.25. About 212,872 shares traded. Neuroderm Ltd (NASDAQ:NDRM) has risen 27.60% since July 17, 2016 and is uptrending. It has outperformed by 10.90% the S&P500.

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The company has market cap of $818.95 million. The Firm is engaged in developing treatments for central nervous system disorders, primarily Parkinson’s disease, as well as other CNS diseases. It currently has negative earnings. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.

Neuroderm Ltd (NASDAQ:NDRM) Ratings Coverage

Among 5 analysts covering NeuroDerm (NASDAQ:NDRM), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. NeuroDerm had 12 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Friday, December 9 with “Buy”. Raymond James initiated the stock with “Outperform” rating in Wednesday, November 11 report. Oppenheimer upgraded it to “Outperform” rating and $42 target in Wednesday, June 14 report. The stock has “Buy” rating by Roth Capital on Thursday, August 6. Jefferies maintained Neuroderm Ltd (NASDAQ:NDRM) on Friday, August 14 with “Buy” rating. Oppenheimer downgraded the shares of NDRM in report on Tuesday, March 7 to “Perform” rating. The firm earned “Buy” rating on Thursday, August 6 by TH Capital. The rating was upgraded by Zacks on Monday, August 10 to “Hold”. Jefferies maintained Neuroderm Ltd (NASDAQ:NDRM) on Thursday, June 8 with “Buy” rating. The rating was maintained by Oppenheimer with “Outperform” on Tuesday, August 11.

More notable recent Neuroderm Ltd (NASDAQ:NDRM) news were published by: Gurufocus.com which released: “Rhenman & Partners Asset Management AB Buys NovoCure, NeuroDerm, Exelixis Inc …” on July 11, 2017, also Globenewswire.com with their article: “Results of NeuroDerm’s ND0612H Phase II Trial Presented in Oral Session at the …” published on June 27, 2017, Globenewswire.com published: “NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson …” on June 08, 2017. More interesting news about Neuroderm Ltd (NASDAQ:NDRM) were released by: Fool.com and their article: “Here’s Why Neuroderm Ltd Stock Is Surging Today” published on March 01, 2017 as well as Streetinsider.com‘s news article titled: “Oppenheimer Upgrades Neuroderm Ltd (NDRM) to Outperform; ‘Alleged Takeover …” with publication date: June 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: